NexImmune jumps on drug development agreement with Selexis SA

Neximmune

08/09/2022 16:07

** Drug developer NexImmune's  NEXI.O  shares rise ~7% to
$1.34 
    ** Co signs service agreement with Switzerland-based Selexis
SA to develop multiple therapies targeting rare cancers and
autoimmune disorders  urn:newsml:reuters.com:*:nBw4r1glTa
    ** Under the agreement, NEXI will leverage Selexis' cell
line development technology to manufacture antibodies for
diseases like acute myeloid leukemia, multiple myeloma, human
papilloma virus associated tumors, among others 
    ** All 4 brokerages covering the stock rate it "buy" or
higher; their median PT is $3.50 - Refinitiv data
    ** Including session gains, stock down ~69% YTD


 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))